Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2021

Open Access 01-12-2021 | Mood Disorders | Research

Heterogeneity in major depression and its melancholic and atypical specifiers: a secondary analysis of STAR*D

Authors: Lorenzo Lorenzo-Luaces, John F. Buss, Eiko I. Fried

Published in: BMC Psychiatry | Issue 1/2021

Login to get access

Abstract

Objectives

The melancholic and atypical specifiers for a major depressive episode (MDE) are supposed to reduce heterogeneity in symptom presentation by requiring additional, specific features. Fried et al. (2020) recently showed that the melancholic specifier may increase the potential heterogeneity in presenting symptoms. In a large sample of outpatients with depression, our objective was to explore whether the melancholic and atypical specifiers reduced observed heterogeneity in symptoms.

Methods

We used baseline data from the Inventory of Depression Symptoms (IDS), which was available for 3,717 patients, from the Sequenced Alternatives to Relieve Depression (STAR*D) trial. A subsample met criteria for MDE on the IDS (“IDS-MDE”; N =2,496). For patients with IDS-MDE, we differentiated between those with melancholic, non-melancholic, atypical, and non-atypical depression. We quantified the observed heterogeneity between groups by counting the number of unique symptom combinations pertaining to their given diagnostic group (e.g., counting the melancholic symptoms for melancholic and non-melancholic groups), as well as the profiles of DSM-MDE symptoms (i.e., ignoring the specifier symptoms).

Results

When considering the specifier and depressive symptoms, there was more observed heterogeneity within the melancholic and atypical subgroups than in the IDS-MDE sample (i.e., ignoring the specifier subgroups). The differences in number of profiles between the melancholic and non-melancholic groups were not statistically significant, irrespective of whether focusing on the specifier symptoms or only the DSM-MDE symptoms. The differences between the atypical and non-atypical subgroups were smaller than what would be expected by chance. We found no evidence that the specifier groups reduce heterogeneity, as can be quantified by unique symptom profiles. Most symptom profiles, even in the specifier subgroups, had five or fewer individuals.

Conclusion

We found no evidence that the atypical and melancholic specifiers create more symptomatically homogeneous groups. Indeed, the melancholic and atypical specifiers introduce heterogeneity by adding symptoms to the DSM diagnosis of MDE.
Literature
1.
Lorenzo-Luaces L. Heterogeneity in the prognosis of major depression: from the common cold to a highly debilitating and recurrent illness. Epidemiol Psychiatr Sci. 2015; 24(6):466–72.PubMedPubMedCentralCrossRef
2.
Lorenzo-Luaces L, DeRubeis RJ, van Straten A, Tiemens B. A prognostic index (pi) as a moderator of outcomes in the treatment of depression: A proof of concept combining multiple variables to inform risk-stratified stepped care models. J Affect Disord. 2017; 213:78–85.PubMedCrossRef
3.
American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington, DC: American Psychiatric Publications; 2013.CrossRef
4.
Zimmerman M, McGlinchey JB, Chelminski I, Young D. Diagnosing major depressive disorder V: applying the DSM-IV exclusion criteria in clinical practice. J Nerv Ment Dis. 2006; 194(7):530–3.PubMedCrossRef
5.
6.
7.
McGlinchey JB, Zimmerman M, Young D, Chelminski I. Diagnosing major depressive disorder VIII: are some symptoms better than others?. J Nerv Ment Dis. 2006; 194(10):785–90.PubMedCrossRef
8.
Horwitz AV, Wakefield JC. The Loss of Sadness: How Psychiatry Transformed Normal Sorrow Into Depressive Disorder. New York: Oxford University Press; 2007.
9.
Shorter E. The doctrine of the two depressions in historical perspective. Acta Psychiatr Scand. 2007; 115:5–13.CrossRef
10.
Cai N, Choi KW, Fried EI. Reviewing the genetics of heterogeneity in depression: operationalizations, manifestations and etiologies. Hum Mol Genet. 2020; 29(R1):10–8.CrossRef
11.
Wakefield JC, Schmitz MF, First MB, Horwitz AV. Extending the bereavement exclusion for major depression to other losses: evidence from the National Comorbidity Survey. Arch Gen Psychiatr. 2007; 64(4):433–40.PubMedCrossRef
12.
Wakefield JC, Schmitz MF. Can the DSM’s major depression bereavement exclusion be validly extended to other stressors?: Evidence from the NCS. Acta Psychiatr Scand. 2013; 128(4):294–305.PubMed
13.
Wakefield JC, Schmitz MF. When does depression become a disorder? using recurrence rates to evaluate the validity of proposed changes in major depression diagnostic thresholds. World Psychiatry. 2013; 12(1):44–52.PubMedPubMedCentralCrossRef
14.
Wakefield JC, Schmitz MF. Normal vs. disordered bereavement-related depression: are the differences real or tautological?. Acta Psychiatr Scand. 2013; 127(2):159–68.PubMedCrossRef
15.
Fried EI, Nesse RM. Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR* D study. J Affect Disord. 2015; 172:96–102.PubMedCrossRef
16.
Zimmerman M, Ellison W, Young D, Chelminski I, Dalrymple K. How many different ways do patients meet the diagnostic criteria for major depressive disorder?. Compr Psychiatry. 2015; 56:29–34.PubMedCrossRef
17.
Fried EI, Coomans F, Lorenzo-Luaces L. The 341 737 ways of qualifying for the melancholic specifier. Lancet Psychiatry. 2020; 7(6):479–80.PubMedCrossRef
18.
Fried EI, Nesse RM. The impact of individual depressive symptoms on impairment of psychosocial functioning. PloS ONE. 2014; 9(2):90311.CrossRef
19.
20.
Kendler KS, Aggen SH, Neale MC. Evidence for multiple genetic factors underlying dsm-iv criteria for major depression. JAMA Psychiatry. 2013; 70(6):599–607.PubMedPubMedCentralCrossRef
21.
Kessing L. Epidemiology of subtypes of depression. Acta Psychiatr Scand. 2007; 115:85–9.CrossRef
22.
American Psychiatric Association. Diagnostic and Statistical Mental Disorder (DSM-III). Washington, DC: American Psychiatric Publications; 1980.
23.
Horwitz AV, Wakefield JC, Lorenzo-Luaces L. History of depression In: DeRubeis RJ, Strunk DR, editors. Oxford Handbook of Mood Disorders. New York: Oxford University Press: 2016. p. 11–23.
24.
American Psychiatric Association. Diagnostic and Statistical Mental Disorder (DSM-IV-TR). Washington, DC: American Psychiatric Publications; 2000.
25.
Pae C-U, Tharwani H, Marks DM, Masand PS, Patkar AA. Atypical depression. CNS Drugs. 2009; 23(12):1023–37.PubMedCrossRef
26.
Uher R, Dernovsek MZ, Mors O, Hauser J, Souery D, Zobel A, Maier W, Henigsberg N, Kalember P, Rietschel M, et al.Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. J Affect Disord. 2011; 132(1-2):112–20.PubMedCrossRef
27.
Cuijpers P, Weitz E, Lamers F, Penninx BW, Twisk J, DeRubeis RJ, Dimidjian S, Dunlop BW, Jarrett RB, Segal ZV, et al.Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression. Depression Anxiety. 2017; 34(3):246–56.PubMedCrossRef
28.
Lamers F, de Jonge P, Nolen WA, Smit JH, Zitman FG, Beekman AT, Penninx BW. Identifying depressive subtypes in a large cohort study: results from the netherlands study of depression and anxiety (nesda). J Clin Psychiatry. 2010; 71(12):1582–9.PubMedCrossRef
29.
Stewart J, McGrath P, Quitkin F, Klein D. Atypical depression: current status and relevance to melancholia. Acta Psychiatr Scand. 2007; 115:58–71.CrossRef
30.
Türkçapar MH, Akdemir A, Örsel SD, Demirergi N, Sirin A, Kiliç EZ, Özbay MH. The validity of diagnosis of melancholic depression according to different diagnostic systems. J Affect Disord. 1999; 54(1-2):101–7.PubMedCrossRef
31.
Baumeister H, Parker G. Meta-review of depressive subtyping models. J Affect Disord. 2012; 139(2):126–40.CrossRef
32.
Bühler J, Seemüller F, Läge D. The predictive power of subgroups: an empirical approach to identify depressive symptom patterns that predict response to treatment. J Affect Disord. 2014; 163:81–7.PubMedCrossRef
33.
34.
Juruena MF, Bocharova M, Agustini B, Young AH. Atypical depression and non-atypical depression: is HPA axis function a biomarker? a systematic review. J Affect Disord. 2018; 233:45–67.PubMedCrossRef
35.
Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, et al.Sequenced treatment alternatives to relieve depression STAR* D: rationale and design. Control Clin Trials. 2004; 25(1):119–42.PubMedCrossRef
36.
Lorenzo-Luaces L, Zimmerman M, Cuijpers P. Are studies of psychotherapies for depression more or less generalizable than studies of antidepressants?. J Affect Disord. 2018; 234:8–13.PubMedCrossRef
37.
Lorenzo-Luaces L, Johns E, Keefe JR. The generalizability of randomized controlled trials of self-guided internet-based cognitive behavioral therapy for depressive symptoms: systematic review and meta-regression analysis. J Med Internet Res. 2018; 20(11):10113.CrossRef
38.
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, et al.Evaluation of outcomes with citalopram for depression using measurement-based care in star* d: implications for clinical practice. Am J Psychiatr. 2006; 163(1):28–40.PubMedCrossRef
39.
Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, Quitkin FM, Wisniewski S, Lavori PW, Rosenbaum JF, et al.Background and rationale for the sequenced treatment alternatives to relieve depression (star*d) study. Psychiatric Clinics. 2003; 26(2):457–94.PubMed
40.
Zimmerman M, Mattia JI. A self-report scale to help make psychiatric diagnoses: the psychiatric diagnostic screening questionnaire. Arch Gen Psychiatr. 2001; 58(8):787–94.PubMedCrossRef
41.
Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The inventory of depressive symptomatology (IDS): psychometric properties. Psychol Med. 1996; 26(3):477–86.PubMedCrossRef
42.
Ulbricht CM, Dumenci L, Rothschild AJ, Lapane KL. Changes in depression subtypes among men in STAR* D: a latent transition analysis. Am J Men’s Health. 2018; 12(1):5–13.CrossRef
43.
Lorenzo-Luaces L. Representing the heterogeneity of depression in treatment research. Acta Psychiatr Scand. 2018; 138(4):360–1.PubMedCrossRef
44.
Lorenzo-Luaces L, Rutter LA, Scalco MD. Carving depression at its joints? psychometric properties of the sydney melancholia prototype index. Psychiatry Neurosci. 2020; 293:113410.
45.
Parker G, McCraw S, Blanch B, Hadzi-Pavlovic D, Synnott H, Rees A-M. Discriminating melancholic and non-melancholic depression by prototypic clinical features. J Affect Disord. 2013; 144(3):199–207.PubMedCrossRef
46.
Arnow BA, Blasey C, Williams LM, Palmer DM, Rekshan W, Schatzberg AF, Etkin A, Kulkarni J, Luther JF, Rush AJ. Depression subtypes in predicting antidepressant response: a report from the iSPOT-D trial. Am J Psychiatr. 2015; 172(8):743–50.PubMedCrossRef
47.
Melartin T, Leskelae U, Rytsaelae H, Sokero P, LestelÄ-Mielonen P, Isometsae E. Co-morbidity and stability of melancholic features in DSM-IV major depressive disorder. Psychol Med. 2004; 34(8):1443–52.PubMedCrossRef
48.
Angst J, Gamma A, Benazzi F, Ajdacic V, Rössler W. Melancholia and atypical depression in the zurich study: epidemiology, clinical characteristics, course, comorbidity and personality. Acta Psychiatr Scand. 2007; 115:72–84.CrossRef
Metadata
Title
Heterogeneity in major depression and its melancholic and atypical specifiers: a secondary analysis of STAR*D
Authors
Lorenzo Lorenzo-Luaces
John F. Buss
Eiko I. Fried
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-021-03444-3

Other articles of this Issue 1/2021

BMC Psychiatry 1/2021 Go to the issue

Research article

Cognitive control and emotional response in attention-deficit/ hyperactivity disorder comorbidity with disruptive, impulse-control, and conduct disorders

Research

Psychiatric emergency admissions during and after COVID-19 lockdown: short-term impact and long-term implications on mental health

Research article

Family involvement and patient-experienced improvement and satisfaction with care: a nationwide cross-sectional study in Danish psychiatric hospitals

Research

Investigating the impact of COVID-19 lockdown on adults with a recent history of recurrent major depressive disorder: a multi-Centre study using remote measurement technology

Research article

Parents’ and medical staff’s experience of adolescents with suicide-related behaviors admitted to a general hospital in China: qualitative study

Research article

Posttraumatic stress disorder among adolescents in Brazil: a cross-sectional study